Here are my suggestions for some of the top articles about immunodeficiency for August 2012:
Primary immunodeficiency disease can be overlooked for years - one patient's story: http://goo.gl/P8VCk - People with primary immunodeficiency also face another hurdle with insurance, largely because antibody replacement therapy is very expensive — $200,000 or more a year.
TLR9 and MyD88 play central role in protective immunity to malaria http://goo.gl/VVF07
Interpretation of antibody response to pneumococcal vaccines - AAAAI Ask the Expert http://goo.gl/J2HEc
T(H)17 deficiency leads to chronic mucocutaneous candidiasis - 2012 JACI review http://goo.gl/F5ydt
ImmunoDeficiencySearch.com - interesting website but not authorship info http://goo.gl/QzSxr
In adult community-acquired pneumonia, the most common pneumococcal serotypes implicated were 14, 1, 8, 3, 19A http://goo.gl/5g4Ze
The reason one gives IgG therapy is to replace missing antibodies, not to build up the protein level of IgG http://goo.gl/51t7f
Prevnar and Pneumovax are not interchangeable when it comes their utility in evaluating humoral immune function http://goo.gl/E3LST
All board-certified allergists / immunologists in the U.S. are certified to treat primary immunodeficiency disorders http://goo.gl/YGLxW
Adults with immunocompromising conditions should receive Prevnar 13, PCV13 in addition to Pneumovax 23, PPSV23 http://goo.gl/DTQwt
Clinical Allergy and Immunology - 2011 free full text review in Ulster Med J. http://goo.gl/1GE0o
Combating chronic T-cell exhaustion http://goo.gl/rIXCD
The immunological life cycle of tuberculosis http://bit.ly/QGLvy6
The articles were selected from my Twitter stream @Allergy and Google Reader RSS subscriptions. Some of the top allergy accounts on Twitter contributed links. I appreciate the curation provided by @JuanCIvancevich @AllergyNet @IgECPD4 @DrAnneEllis @AACMaven @AllergieVoeding @allergistmommy @mrathkopf @wheezemd.
Please feel free to send suggestions for articles to email@example.com and you will receive acknowledgement in the next edition of this publication.
Image source: Wikipedia.